Climate Change Data

Pharmanovia

Climate Impact & Sustainability Data (2022)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:12,477 tCO2e/year
Scope 1 Emissions:60 tCO2e/year
Scope 2 Emissions:3 tCO2e/year
Scope 3 Emissions:12,414 tCO2e/year
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Patient health and safety
  • Product quality
  • Ethical business practices
  • Product Innovation
  • Human capital and culture
  • Governance
  • Responsible supply chain
  • Environmental Impact and sustainability

Environmental Achievements

  • Reduced upstream transportation emissions by 18% through air-to-sea freight pilot program.
  • 64% of sold packs had secondary packaging components made from either a partial or fully recycled material.

Social Achievements

  • Launched Wellness Wednesdays, a meeting-free Wednesday afternoon initiative.
  • Rolled out a company-wide employee social mobility survey.
  • 98% employee completion rate for mandatory compliance training, including ESG modules.
  • 48% of 56 promotions in 2022 were women.

Governance Achievements

  • Formalized Internal Audit function, conducting seven audits in 2022.
  • Launched a new company-wide governance system and ethics and compliance management system (Navex).

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Reduce absolute Scope 1 and 2 emissions by 42% by 2030 from a 2021 base year.
  • Measure and manage Scope 3 emissions, ensuring no growth in absolute Scope 3 emissions.
  • Offset 100% of remaining emissions by 2030.
Short-term Goals:
  • Increase the number of sea shipments to 40% by the end of 2023.

Environmental Challenges

  • Resource challenges impacting the full rollout of the Health and Wellbeing program.
  • Initial UK-centric approach to the Health and Wellbeing program.
  • Decreased employee survey participation rate (from 82% to 68.4%).
  • Increased Scope 3 emissions (purchased pharmaceuticals) by 31%.
Mitigation Strategies
  • Designed a robust global Health and Wellness program tailored by country for 2023 launch.
  • Plan to use a more direct and tailored approach for employee surveys in 2023.
  • 71% of suppliers have set or committed to Science Based Targets.
  • Continued efforts to switch from air to sea freight for product transportation.

Supply Chain Management

Supplier Audits: 100% of API manufacturers and 97% of finished product manufacturers and distributors audited in 2022.

Responsible Procurement
  • Rigorous due diligence on all prospective business partners.
  • Scorecard ESG criteria for supplier selection.
  • Quarterly risk review meetings to monitor supplier performance.
  • PC3 risk monitoring system (performance, conformance, compliance, and collaboration).

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: GRI

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • 3
  • 7
  • 8
  • 9
  • 10
  • 12
  • 13
  • 16

Pharmanovia's initiatives contribute to these SDGs through various commitments detailed in the report.

Sustainable Products & Innovation

  • New buccal film delivery system.

Awards & Recognition

  • Not disclosed